J. Sramek

N. Cutler, J. Sramek, V. Zarotsky, 2003, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

A Randomized Evaluation of the Effects of Six Antipsychotic Agents on QTc, In the Absence and Presence of Metabolic Inhibition

R. Anziano, N. Cutler, T. Shiovitz, 2004, Journal of clinical psychopharmacology.

Review of drug development and therapeutic role of cholinesterase inhibitors in Alzheimer's disease

N. Cutler, J. Sramek, V. Zarotsky, 2002 .

Muscarinic M1-Receptor Agonists

N. Cutler, J. Sramek, 1995 .

Gender Differences in Depression and Antidepressant Pharmacokinetics and Adverse Events

N. Cutler, J. Sramek, E. J. Frackiewicz, 2000, The Annals of pharmacotherapy.

Pharmacokinetics of co-administered didanosine and stavudine in HIV-seropositive male patients.

N. Cutler, S. Kaul, J. Sramek, 1994, British journal of clinical pharmacology.

Adverse Effects of Antipsychotic Agents

G. Simpson, J. Sramek, E. Pi, 1981, Drugs.

The impact of gender on antidepressants.

N. Cutler, J. Sramek, 2011, Current topics in behavioral neurosciences.

Penetration of trovafloxacin into cerebrospinal fluid in humans following intravenous infusion of alatrofloxacin

N. Cutler, J. Sramek, T. Wardle, 1997, Antimicrobial agents and chemotherapy.

The status of ongoing trials for mild cognitive impairment

N. Cutler, J. Sramek, A. Veroff, 2001, Expert opinion on investigational drugs.

Mild Cognitive Impairment: Emerging Therapeutics

N. Cutler, J. Sramek, A. Veroff, 2000, The Annals of pharmacotherapy.

Neuroleptic-induced hypothermia associated with amelioration of psychosis in schizophrenia.

S. Potkin, M. Buchsbaum, E. Hazlett, 1988, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

Pleocytosis in cerebrospinal fluid following multiple lumbar punctures in healthy volunteers

Josephine M. Palasota, N. Cutler, J. Sramek, 2015, Journal of the Neurological Sciences.

Reactions to Antidepressants: Monoamine Oxidase Inhibitors

J. Sramek, E. Pi, F. L. Tornatore, 1987 .

Ongoing trials in Alzheimer’s disease

N. Cutler, J. Sramek, 2000, Expert opinion on investigational drugs.

Recent Developments in the Drug Treatment of Alzheimer’s Disease

N. Cutler, J. Sramek, 1999, Drugs & aging.

Animal Models and Procedures for CNS Disorders

N. Cutler, P. Bieck, H. Riordan, 2010 .

Rapid Onset Psychosis Following Abrupt Clozapine Withdrawal

N. Cutler, J. Sramek, T. L. Welke, 1996 .

Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms.

J. Amsterdam, S. Stahl, R. Weisler, 1996, The Journal of clinical psychiatry.

Reactions to Antiparkinson Agents

J. Sramek, E. Pi, F. L. Tornatore, 1987 .

Meta‐analysis of the safety and tolerability of two dose regimens of buspirone in patients with persistent anxiety

N. Cutler, J. Sramek, W. Hong, 1999, Depression and anxiety.

Serum homovanillic acid concentrations in carbamazepine-treated chronic schizophrenics

S. Potkin, D. Pickar, J. Sramek, 1989, Biological Psychiatry.

Time-dependent autoinduction of carbamazepine in schizophrenia

J. Sramek, J. Herrera, T. Tran-Johnson, 1987, Drug intelligence & clinical pharmacy.

Neuroleptic dosing in Hispanic and Asian Inpatients with schizophrenia.

J. Sramek, J. Herrera, Y. Collazo, 1996, The Mount Sinai journal of medicine, New York.

Psychomotor and Memory Effects of Two Adinazolam Formulations Assessed by a Computerized Neuropsychological Test Battery

N. Cutler, J. Fleishaker, J. Sramek, 1993, Journal of clinical pharmacology.

Evaluation of Cycloserine in the Treatment of Alzheimer's Disease

R. Herting, N. Cutler, J. Sramek, 1995, Journal of geriatric psychiatry and neurology.

F1eroxacin Treatment of Stage IV Pressure Ulcers with Associated Osteomyelitis

N. Cutler, J. Sramek, R. Seifert, 1994, The Annals of pharmacotherapy.

Lurasidone in post-menopausal females with major depressive disorder with mixed features: Post-hoc analysis of a placebo-controlled trial

A. Pikalov, N. Cutler, A. Loebel, 2017, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Reactions to Antidepressants: Tricyclic and Tetracyclic

J. Sramek, E. Pi, F. L. Tornatore, 1987 .

Reactions to Antipsychotics

J. Sramek, E. Pi, F. L. Tornatore, 1987 .

Abnormal EEG responses to photic stimulation in schizophrenic patients.

R Isenhart, C A Sandman, C. Sandman, 1990, Schizophrenia bulletin.

A Bioequivalence Study of Brand and Generic Clozapine in Patients with Schizophrenia

N. Cutler, T. Shiovitz, H. Schran, 1999 .

Sex differences in the psychopharmacological treatment of depression

N. Cutler, J. Sramek, M. Murphy, 2016, Dialogues in clinical neuroscience.

Establishing the maximum tolerated dose of lesopitron in patients with generalized anxiety disorder: a bridging study.

A. Carrington, K. Bolles, N. Cutler, 1996, Journal of clinical psychopharmacology.

Anxiolytic Compounds: Perspectives in Drug Development

N. Cutler, J. Sramek, N. Kurtz, 1996 .

Xanomeline, A Specific M1 Agonist: Early Clinical Studies

L. Farde, T. Gillespie, N. Cutler, 1994 .

Monitoring of Acute Migraine Attacks: Placebo Response and Safety Data

N. Cutler, J. Sramek, S. Jhee, 1998, Headache.

Generalised anxiety disorder: treatment options.

N. Cutler, J. Sramek, V. Zarotsky, 2002, Drugs.

A New Assessment Tool for Neuropsychopharmacologic Research: The Computerized Neuropsychological Test Battery

N. Cutler, J. Sramek, A E Veroff, 1991, Journal of geriatric psychiatry and neurology.

A phase II multicenter dose-finding, efficacy and safety trial of ipsapirone in outpatients with generalized anxiety disorder

N. Cutler, J. Hesselink, J. Sramek, 1994, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Pramipexole in patients with early Parkinson's disease.

J. Hubble, W. Koller, C. Goetz, 1995, Clinical neuropharmacology.

Neuroleptic Plasma Concentrations and Clinical Response: In Search of a Therapeutic Window

S. Potkin, J. Sramek, R. Hahn, 1988, Drug intelligence & clinical pharmacy.

Oral Sumatriptan Pharmacokinetics in the Migraine State

N. Cutler, J. Sramek, E. Hussey, 1999 .

Efficacy and safety of two dosing regimens of buspirone in the treatment of outpatients with persistent anxiety.

N. Cutler, J. Sramek, E. Frackiewicz, 1997, Clinical therapeutics.

High Potency Neuroleptics and Violence in Schizophrenics

J. Sramek, C. Heh, Jerome F. Costa, 1988, The Journal of nervous and mental disease.

Pharmacodynamics and drug development : perspectives in clinical pharmacology

N. Cutler, J. Sramek, P. Narang, 1994 .

Ethnicity and antidepressant response.

J. Sramek, E. Pi, 1996, The Mount Sinai journal of medicine, New York.

Safety and tolerability of metrifonate in patients with Alzheimer's disease: results of a maximum tolerated dose study.

B. Gulanski, N. Cutler, F. Bieber, 1998, Life sciences.

Evaluation of Multiple Doses of Milacemide in the Treatment of Senile Dementia of the Alzheimer's Type

F. Matsuo, H. Hendrie, R. Herting, 1993, Journal of geriatric psychiatry and neurology.

The effect of naltrexone on sleep parameters in healthy male volunteers.

N. Cutler, H. Riordan, J. Sramek, 2014, Journal of clinical psychopharmacology.

Understanding Alzheimer's disease

N. Cutler, J. Sramek, 1996 .

Efficacy of xanomeline in Alzheimer disease: cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB).

W W Offen, W. Offen, N. Cutler, 1998, Alzheimer disease and associated disorders.

Review of the next generation of Alzheimer's disease therapeutics: challenges for drug development

N. Cutler, J. Sramek, 2001, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Cholinesterase Inhibitors: A Therapeutic Strategy for Alzheimer Disease

N. Cutler, J. Sramek, Wanda J Krall, 1999, The Annals of pharmacotherapy.

Efficacy and Safety of BMY 21,502 in Alzheimer Disease

N. Cutler, J. Sramek, Amy E Veroff, 1996, The Annals of pharmacotherapy.

Pilot study of a CCKB antagonist in patients with panic disorder: preliminary findings.

N. Cutler, S. Reines, J. Sramek, 1994, Anxiety.

The Use of the Computerized Neuropsychological Test Battery (CNTB) in an Efficacy and Safety Trial of BMY 21,502 in Alzheimer's Disease

N. Cutler, J. Sramek, A E Veroff, 1993, Annals of the New York Academy of Sciences.

Comparison of quantitative methodologies to define chronic pressure ulcer measurements.

N. Cutler, J. Sramek, R. Brunelle, 1993, Decubitus.

Depression in the course of treatment of generalized anxiety disorder with lorazepam, ipsapirone, and placebo: Results from a multicenter trial

N. Cutler, J. Hesselink, J. Sramek, 1993 .

Neuroleptic dosing in Asian and Hispanic outpatients with schizophrenia.

J. Sramek, S. Ruiz, J. Herrera, 1996, The Mount Sinai journal of medicine, New York.

Neuroleptic dosage for Asians: a failure to replicate.

G. Simpson, M. Sayles, J. Sramek, 1986, The American journal of psychiatry.

Distinct mechanism for antidepressant activity by blockade of central substance P receptors.

R G Hill, David J. Smith, J. Feighner, 1998, Science.

Psychotic Exacerbation with Haloperidol

J. Sramek, F. L. Tornatore, Catherine Bertho-Gébara, 1981, Drug intelligence & clinical pharmacy.

A bridging study of fananserin in schizophrenic patients.

N. Cutler, J. Sramek, J. Hourani, 1998, Psychopharmacology bulletin.

An evaluation of the anxiolytic SC 48,274 in generalized anxiety disorder (GAD)

N. Cutler, J. Sramek, C. Benes, 1994, Progress in Neuro-psychopharmacology and Biological Psychiatry.

Potential for Adverse Events in Patients with Generalized Anxiety Disorder

N. Cutler, J. Sramek, E. J. Frackiewicz-Koziol, 1998, The Annals of Pharmacotherapy.

Exploratory Biomarker Study of the Triple Reuptake Inhibitor SEP‐432 Compared to the Dual Reuptake Inhibitor Duloxetine in Healthy Normal Subjects

M. Versavel, N. Cutler, P. Bieck, 2016, CNS neuroscience & therapeutics.

'Loads' alert.

J. Sramek, G. M. Simpson, A. Khajawall, 1982, The Western journal of medicine.

Persistence of Plasma Neuroleptic Levels after Drug Discontinuation

J. Sramek, J. Herrera, J. Costa, 1987 .

Critical Pathways to Success in CNS Drug Development

N. Cutler, P. Bieck, H. Riordan, 2010 .

The Impending Crisis in CNS Drug Development

N. Cutler, P. Bieck, H. Riordan, 2010 .

Detection of Benzodiazepines in Human Hair by Radioimmunoassay

N. Cutler, J. Sramek, N R Cutler, 1992, The Annals of pharmacotherapy.

Prevalence of tardive dyskinesia among three ethnic groups of chronic psychiatric patients.

N. Cutler, J. Sramek, P. Pinanong, 1991, Hospital & community psychiatry.

Investigator Perspective on MTD: Practical Application of an MTD Definition—Has It Accelerated Development?

N. Cutler, J. Sramek, 2000, Journal of clinical pharmacology.

Effect of lithium on leukocytes: a two-year follow-up.

G. Simpson, J. Sramek, E. Pi, 1983, The Journal of clinical psychiatry.